Association of pl6 gene methylation with prostate cancer risk: A meta-analysis

Journal of B.U.ON.

Volumn 20, Issue 4, 2015, Pages 1074-1080

  Feng, Wen ^a   Han, Zhi ^a   Zhu, Ruixia ^a   Liu, Peiyue ^a   Liu, Sihai ^a  

^a Central Hospital   (China)

Author keywords

Methylation; Pl6; Prostate cancer; Susceptibility

Indexed keywords

PROTEIN P16; TUMOR MARKER;

ARTICLE; ASIAN; CANCER RISK; CAUCASIAN; DISEASE ASSOCIATION; EMBASE; ETHNIC GROUP; HUMAN; MEDLINE; META ANALYSIS; METHYLATION; PROSTATE CANCER; PUBLISHING; SYSTEMATIC REVIEW; WEB OF SCIENCE; DNA METHYLATION; GENETICS; MALE; PROSTATIC NEOPLASMS; RISK; TUMOR SUPPRESSOR GENE;

DNA METHYLATION; GENES, P16; HUMANS; MALE; PROSTATIC NEOPLASMS; PUBLICATION BIAS; RISK;

EID: 84943224428     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2. Gronberg H. Prostate cancer epidemiology. Lancet 2003;361:859-864.
3. Schaid DJ. The complex genetic epidemiology of prostate cancer. Hum Mol Genet 2004;13 Spec No 1:R103-121.
4. Park JY. Promoter hypermethylation in prostate cancer. Cancer Control 2010;17:245-255.
5. Cairns P, Mao L, Merlo A et al. Rates of pl6 (MTS1) mutations in primary tumors with 9p loss. Science 1994;265:415-417.
6. Geisler SA, Olshan AF, Weissler MC et al. pl6 and p53 protein expression as prognostic indicators of survival and disease recurrence from head and neck cancer. Clin Cancer Res 2002;8:3445-3453.
7. Jarrard DF, Bova GS, Ewing CM et al. Deletional, mutational, and methylation analyses of CDKN2 (p16/MTS1) in primary and metastatic prostate cancer. Genes Chromosomes Cancer 1997;19:90-96.
8. Liggett WH, Jr., Sidransky D. Role of the p16 tumor suppressor gene in cancer. J Clin Oncol 1998;16:1197-1206.
9. Herman JG, Merlo A, Mao L et al. Inactivation of the CDKN2/pl6/MTSl gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 1995;55:4525-4530.
10. Merlo A, Herman JG, Mao L et al. 5' CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTSl in human cancers. Nat Med 1995;1:686-692.
11. Shim YH, Kang GH, Ro JY. Correlation of pl6 hypermethylation with pl6 protein loss in sporadic gastric carcinomas. Lab Invest 2000;80:689-695.
12. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-560.
13. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-188.
14. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959;22:719-748.
15. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-634.
16. Duval S, Tweedie R. Trim and fill: A simple funnel-plotbased method of testing and adjusting for publication bias in meta-analysis. Biometrics 2000;56:455-463.
17. Delgado-Cruzata L, Hruby GW, Gonzalez K et al. DNA methylation changes correlate with Gleason score and tumor stage in prostate cancer. DNA Cell Biol 2012;31:187-192.
18. Florl AR, Steinhoff C, Muller M et al. Coordinate hypermethylation at specific genes in prostate carcinoma precedes LINE-1 hypomethylation. Br J Cancer 2004;91:985-994.
19. Rusiecki JA, Al-Nabhani M, Tarantini L, Chen L, Baccarelli A, Al-Moundhri MS. Global DNA methylation and tumor suppressor gene promoter methylation and gastric cancer risk in an Omani Arab population. Epigenomics 2011;3:417-429.
20. Vasiljevic N, Wu K, Brentnall AR et al. Absolute quantitation of DNA methylation of 28 candidate genes in prostate cancer using pyrosequencing. Dis Markers 2011;30:151-161.
21. Ameri A, Alidoosti A, Hosseini SY et al. Prognostic Value of Promoter Hypermethylation of Retinoic Acid Receptor Beta (RARB) and CDKN2 (pl6/MTSl) in Prostate Cancer. Chin J Cancer Res 2011;23:306-311.
22. Cho NY, Kim BH, Choi M et al. Hypermethylation of CpG island loci and hypomethylation of LINE-1 and Alu repeats in prostate adenocarcinoma and their relationship to clinicopathological features. J Pathol 2007;211:269-277.
23. Hoque MO, Topaloglu O, Begum S et al. Quantitative methylation-specific polymerase chain reaction gene patterns in urine sediment distinguish prostate cancer patients from control subjects. J Clin Oncol 2005;23:6569-6575.
24. Jeronimo C, Henrique R, Hoque MO et al. A quantitative promoter methylation profile of prostate cancer. Clin Cancer Res 2004;10:8472-8478.
25. Kekeeva TV, Popova OP, Shegai PV et al. [Abberant methylation of pl6, HIC1, N33 and GSTP1 genes in tumor epitelium and tumor-associated stromal cells of prostate cancer]. Mol Biol (Mosk) 2007;41:79-85.
26. Maruyama R, Toyooka S, Toyooka KO et al. Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features. Clin Cancer Res 2002;8:514-519.
27. Murphy TM, Sullivan L, Lane C et al. In silico analysis and DHPLC screening strategy identifies novel apoptotic gene targets of aberrant promoter hypermethylation in prostate cancer. Prostate 2011;71:1-17.
28. Roupret M, Hupertan V, Yates DR et al. Molecular detection of localized prostate cancer using quantitative methylation-specific PCR on urinary cells obtained following prostate massage. Clin Cancer Res 2007;13:1720-1725.
29. Yao Q, He XS, Zhang JM, He J. [Promotor hypermethylation of E-cadherin, pl6 and estrogen receptor in prostate carcinoma]. Zhonghua Nan Ke Xue 2006;12:28-31.
30. Yaqinuddin A, Qureshi SA, Pervez S, Bashir MU, Nazir R, Abbas F. Frequent DNA Hypermethylation at the RASSFIA and APC Gene Loci in Prostate Cancer Patients of Pakistani Origin. ISRN Urol 2013;2013:627249.
31. Yegnasubramanian S, Kowalski J, Gonzalgo ML et al. Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res 2004;64:1975-1986.
32. Lau J, Ioannidis JP, Schmid CH. Summing up evidence: one answer is not always enough. Lancet 1998;351:123-127.
33. Bruce JL, Hurford RK, Jr., Classon M, Koh J, Dyson N. Requirements for cell cycle arrest by pl6INK4a. Mol Cell 2000;6:737-742.
34. Kamb A, Gruis NA, Weaver-Feldhaus J et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994;264:436-440.
35. Straume O, Sviland L, Akslen LA. Loss of nuclear pl6 protein expression correlates with increased tumor cell proliferation (Ki-67) and poor prognosis in patients with vertical growth phase melanoma. Clin Cancer Res 2000;6:1845-1853.
36. Partin AW, Oesterling JE. The clinical usefulness of prostate specific antigen: update 1994. J Urol 1994;152:1358-1368.
37. Dhanasekaran SM, Barrette TR, Ghosh D et al. Delineation of prognostic biomarkers in prostate cancer. Nature 2001;412:822-826.
38. Xing X, Cai W, Shi H et al. The prognostic value of CD-KN2A hypermethylation in colorectal cancer: a meta-analysis. Br J Cancer 2013;108:2542-2548.
39. Lou-Qian Z, Rong Y, Ming L, Xin Y, Feng J, Lin X. The prognostic value of epigenetic silencing of pl6 gene in NSCLC patients: a systematic review and meta-analysis. PLoS One 2013;8(1):e54970.
40. Widschwendter M, Jones PA. DNA methylation and breast carcinogenesis. Oncogene 2002;21:5462-5482.
41. Das PM, Singal R. DNA methylation and cancer. J Clin Oncol 2004;22:4632-4642.